Status:
UNKNOWN
Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases
Lead Sponsor:
Shandong Cancer Hospital and Institute
Collaborating Sponsors:
Shandong Provincial Hospital
Qilu Hospital of Shandong University
Conditions:
Brain Metastases
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Brain metastases are the most common intracranial tumors in adults. Whole-brain radiation therapy (WBI) increases the median survival of patients with brain metastases up to 3-6 months, but WBI can le...
Detailed Description
In this prospective phase 1 study evaluating the safety and efficacy of selective brain radiotherapy in NSCLCs with limited brain metastases, patients will received selective brain radiotherapy based ...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed NSCLC with MRI confirmed new brain metastases a life expectancy of at least 3 months; adequate organ function according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.
Exclusion
- radiologically or pathologically confirmed metastases in the spinal cord or meninges obvious hernia formation risk previously received brain surgery or radiotherapy a history or presence of poorly controlled systemic diseases pregnant patients
Key Trial Info
Start Date :
December 2 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03414944
Start Date
December 2 2016
End Date
September 30 2018
Last Update
January 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Cancer Hospital
Jin'an, Shandong, China, 250117